Last updated: June 8, 2026
Executive summary: The clotrimazole + betamethasone dipropionate combination drug is supplied through two main channels: (1) API and key intermediate manufacturers that provide clotrimazole and betamethasone dipropionate (BDP) separately, and (2) contract manufacturing organizations (CMOs) that formulate and pack the finished product (cream, ointment, topical solution, and combination SKUs). Public supplier visibility is strongest for finished-dose packers and established generic brands; granular API supplier lists are inconsistently disclosed across markets.
Key risk for sourcing: the BDP portion is the more constrained input because betamethasone dipropionate is a steroidal API with tighter regulatory and quality expectations than imidazole APIs. Many suppliers therefore market as finished-dose manufacturers while relying on a limited set of upstream API providers.
Who supplies clotrimazole and betamethasone dipropionate combination creams and ointments?
Direct finished-product suppliers (typical roles in the supply chain):
- Brand and generic marketing authorization holders (hold the label and distribution approvals in each market).
- Contract packers and manufacturers (formulate, fill, and pack creams/ointments).
- Wholesalers and parallel import distributors (buy finished goods and distribute by license).
Where supplier lists are most actionable:
- National regulator databases and local tender awards identify the actual labeled manufacturer for a specific country and dosage form.
- For global sourcing, supplier registries and CMO qualification pages often list “manufacturing site” rather than upstream API sites.
Which companies are active in topical clotrimazole + betamethasone dipropionate finished products?
This combination is sold under multiple trade names globally and often as generic equivalents. Market supply commonly includes:
- Multi-market generic manufacturers with topical dermatology portfolios.
- Steroid and dermatology-focused CMOs that handle semisolid manufacturing (mixing, milling, homogenization, filling, and batch release).
Practical sourcing approach used by buyers: select the labeled manufacturer and verify the specific API sources (clotrimazole and BDP) via supplier qualification dossiers under quality agreements and incoming testing specs.
What suppliers provide the clotrimazole API used in the combination?
API supply pattern:
- Clotrimazole is an imidazole antifungal API produced at scale by multiple global API makers.
- Upstream availability is typically broader than BDP because clotrimazole has more route variability and mature manufacturing ecosystems.
Typical supplier categories:
- API manufacturers producing clotrimazole as a standalone API.
- API intermediates producers that produce clotrimazole via contracted conversion steps.
- Vertical integrators that also supply finished-dose topical dermatology products.
Buyer verification points:
- Polymorph/crystal form consistency.
- Impurity profile aligned to pharmacopeia monographs and the finished product specification.
- Batch-to-batch control on residual solvents and genotoxicity-relevant impurities.
What suppliers provide betamethasone dipropionate (BDP) for topical combinations?
API supply pattern:
- BDP API is a corticosteroid API with more constrained supply relative to many other dermatology actives.
- Supply risk is concentrated in fewer qualified vendors that can meet stringent analytical and GMP expectations.
Typical supplier categories:
- Steroid-active API manufacturers.
- Specialty hormone and corticosteroid API producers.
- Some manufacturers supply both clotrimazole and BDP bundles into finished-dose contracts, but separate sourcing remains common.
Buyer verification points:
- Controls for steroid-related impurities.
- Stability of BDP in semisolid dosage forms and compatibility with the cream/ointment vehicle.
- GMP batch release data for topical steroid APIs.
How do API suppliers connect to finished-dose manufacturers for clotrimazole + betamethasone dipropionate?
Common manufacturing models:
- Model A: Separate API supply. API suppliers sell clotrimazole and BDP to a finished-dose CMO that formulates and packages.
- Model B: API + formulation package. A supplier provides API, excipients, and technical support under a development and scale-up agreement.
- Model C: Brand manufacturing outsourcing. The brand owner contracts a CMO for manufacturing and relies on the CMO’s qualified API supply network.
Key due diligence deliverables:
- CoA for each API batch.
- GMP certificate for API manufacturing sites.
- Audit reports or qualification status for the finished-dose CMO and API vendor(s).
What formulations are used and which supplier types make them?
Dosage forms buyers procure most:
- Cream
- Ointment
- (In some jurisdictions) topical solution or specialized semisolids
Formulation implications for suppliers:
- Semisolid topical manufacturing needs validated mixing and homogenization processes to prevent phase separation and ensure uniform steroid distribution.
- Label and specification drive whether suppliers use oil-in-water cream bases or oleaginous ointment bases.
Supplier fit:
- CMOs with dermatology semi-solid lines.
- Sites with validated filling systems for tubes, jars, and multi-dose packaging formats.
Which contract manufacturing organizations (CMOs) handle clotrimazole + betamethasone dipropionate topical products?
Cohort of CMO capabilities typically required:
- GMP semisolid manufacturing suites.
- In-process controls for viscosity, uniformity, and particle size.
- Stability testing and accelerated studies for steroid-containing topical products.
- Packaging line compatibility for aluminum laminate tubes, polypropylene tubes, and laminated pouches.
What buyers ask for during qualification:
- Evidence of prior topical steroid experience.
- Batch records and process validation packages for semisolids.
- Ability to support tech transfer and regulatory submissions.
What regulatory listings identify the actual labeled manufacturer and supplier for each market?
Where the answer is usually discoverable:
- FDA Orange Book for the US references only where applicable to approved products (often showing listed drug reference and patents, not API suppliers).
- EMA/Member State product databases list the marketing authorization holder and the manufacturing site(s).
- National medicines agency lists (UK MHRA, etc.) show manufacturing authorization details for specific labeled products.
Procurement implication: the “supplier” in a tender or purchase order is the labeled manufacturer for that market product strength and dosage form, not necessarily the upstream API producer.
Supplier selection: what matters most for clotrimazole + betamethasone dipropionate?
Selection criteria used in procurement and QA:
- Regulatory track record for topical steroid products.
- Consistency of BDP API and controlled impurity profiles.
- Uniformity and stability in the specific vehicle (cream vs ointment).
- Supply continuity (API lead times and backup vendor qualification).
- Documentation depth (GMP certificates, CoAs, validation summaries, stability reports).
Commercial risk:
- Quality failures in steroid-containing products can trigger recalls and market withdrawals.
- Shortages usually manifest as constrained availability at the finished-dose level because dosing units are purchased through distribution channels and tender pipelines.
Key Takeaways
- Supplier mapping for clotrimazole + betamethasone dipropionate splits into upstream API sourcing (clotrimazole and BDP separately) and downstream finished-dose manufacturing and packing (cream/ointment).
- BDP supply is more constrained than clotrimazole, making BDP-qualified vendors a key sourcing bottleneck.
- The most actionable “supplier” for procurement is the labeled manufacturer for the target country and dosage form, while upstream API suppliers are confirmed via qualification and quality agreements.
- CMO selection hinges on semisolid GMP capability, steroid topical experience, and validated uniformity and stability controls.
FAQs
-
How can I identify the labeled manufacturer of clotrimazole + betamethasone dipropionate cream in a specific country?
Check the relevant national medicines register or product database for the marketing authorization and manufacturing site for the exact strength and dosage form.
-
Is clotrimazole API easier to source than betamethasone dipropionate for this combination?
In practice, BDP tends to have fewer qualified supply options relative to clotrimazole due to steroid API constraints and quality expectations.
-
What manufacturing capabilities are required for semisolid topical steroid products?
GMP semisolid manufacturing with validated mixing/homogenization, uniformity controls, and compatible tube or jar filling lines.
-
Do API suppliers typically provide formulation support for the combination product?
Many API vendors offer technical packages, but formulation is most often delivered through a CMO or in-house development team that owns the validated process.
-
What documentation matters most when qualifying suppliers for this combination?
GMP certificates for API and finished-dose sites, batch CoAs, impurity/solvent controls, stability results for the chosen vehicle, and audit/qualification evidence.
References (APA)
- U.S. Food and Drug Administration. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
- European Medicines Agency. (n.d.). EU/EEA product information and EPARs. EMA. https://www.ema.europa.eu/
